Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non-Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase 2 Study (GFPC 0505)

详细信息    查看全文

• 作者：Christos Chouaid¹ ; ^{christos.chouaid@sat.aphp.fr} ; Hervé ; Le Caer² ; Romain Corre³ ; Jacquy Crequit⁴ ; Chrystelle Locher⁵ ; Lionel Falchero⁶ ; Cecile Dujon⁷ ; Henri Berard⁸ ; Isabelle Monnet⁹ ; Alain Vergnenegre¹⁰
• 关键词：Cost-utility ; Elderly patients ; Erlotinib ; Phase II trial
• 刊名：Clinical Lung Cancer
• 出版年：2013
• 出版时间：March, 2013
• 年：2013
• 卷：14
• 期：2
• 页码：103-107
• 全文大小：781 K

文摘

Background

A large proportion of elderly patients (>70 years) with newly diagnosed NSCLC are shown to be frail by a comprehensive geriatric assessment. This population is more vulnerable to adverse effects of chemotherapy and might thus benefit more from targeted therapy. The objective of this study was to assess the cost-effectiveness of erlotinib followed by chemotherapy after progression, compared with the reverse strategy, in frail elderly patients with advanced NSCLC participating in a prospective randomized phase II trial (GFPC 0505).

Materials and Methods

Outcomes (progression-free survival and overall survival) and costs (limited to direct medical costs, from the third-party payer perspective) were collected prospectively until second progression. Costs after progression and health utilities (based on disease states and grade 3-4 toxicities) were derived from the literature.

Results

Median overall survival, QALYs, and total costs for the erlotinib-first strategy were 3.9 months, 0.33, and €15,233, respectively, compared with 4.4 months, 0.35, and €15,363 for the chemotherapy-first strategy. There was no significant difference between the 2 strategies in term of cost-effectiveness (respectively €47,381 and €44,350 per QALY).

Conclusion

No difference in cost-effectiveness was found between an erlotinib-first strategy and a chemotherapy-first strategy in frail elderly patients with NSCLC.